Literature DB >> 12697738

Sensitizing antigen-specific CD8+ T cells for accelerated suicide causes immune incompetence.

Christoph Wasem1, Diana Arnold, Leslie Saurer, Nadia Corazza, Sabine Jakob, Simon Herren, Claudio Vallan, Christoph Mueller, Thomas Brunner.   

Abstract

Death receptor-mediated activation-induced apoptosis of antigen-specific T cells is a major mechanism of peripheral tolerance induction and immune homeostasis. Failure to undergo activation-induced cell death (AICD) is an important underlying cause of many autoimmune diseases. Thus, enhancing the T cell's own suicide mechanism may provide an efficient therapy for the treatment of autoimmune diseases. Bisindolylmaleimide VIII (Bis VIII), a PKC inhibitor, can sensitize T cells for death receptor-induced apoptosis and thus can inhibit the development of T cell-mediated autoimmune disease in vivo. In this study, we have analyzed the functional consequences of accelerated suicide for a protective CD8+ T cell-mediated immune response. Our data indicate that CD8+ T cells are sensitized by Bis VIII to AICD, both in vitro and in vivo. The sensitizing effect of Bis VIII appears to be mediated by specific downmodulation of the antiapoptotic molecule cellular FLICE-like inhibitory protein (cFLIP(L)). Importantly, Bis VIII administration during an acute lymphocytic choriomeningitis virus (LCMV) infection causes the depletion of virus-specific CD8+ T cells and subsequently impaired cytotoxicity and virus clearance. We conclude that resistance to death receptor-induced apoptosis is crucial for the efficient induction of a protective immune response, and that Bis VIII-based immunotherapies have to be applied under well-controlled conditions to avoid the induction of immune incompetence and the inability to respond to pathogen infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697738      PMCID: PMC152931          DOI: 10.1172/JCI16344

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

Review 1.  The role of CD4 vs. CD8 T cells in IDDM.

Authors:  F S Wong; C A Janeway
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

2.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

4.  Accelerating the induction of Fas-mediated T cell apoptosis: a strategy for transplant tolerance?

Authors:  H P Carroll; S Ali; J A Kirby
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 5.  The role of Fas ligand in immune privilege.

Authors:  D R Green; T A Ferguson
Journal:  Nat Rev Mol Cell Biol       Date:  2001-12       Impact factor: 94.444

6.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

Authors:  D J Van Antwerp; S J Martin; T Kafri; D R Green; I M Verma
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

7.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

Authors:  Y Refaeli; L Van Parijs; C A London; J Tschopp; A K Abbas
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

Review 8.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

9.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

10.  Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis.

Authors:  X Zhang; T Brunner; L Carter; R W Dutton; P Rogers; L Bradley; T Sato; J C Reed; D Green; S L Swain
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

View more
  7 in total

1.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.

Authors:  Badiga Venkata Aruna; Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

2.  T helper lymphocytes rescue CTL from activation-induced cell death.

Authors:  Richard Kennedy; Esteban Celis
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

3.  pPKCα mediated-HIF-1α activation related to the morphological modifications occurring in neonatal myocardial tissue in response to severe and mild hyperoxia.

Authors:  S Zara; V Macchi; R De Caro; M Rapino; A Cataldi; A Porzionato
Journal:  Eur J Histochem       Date:  2012-01-31       Impact factor: 3.188

4.  Intestinal epithelial cells synthesize glucocorticoids and regulate T cell activation.

Authors:  Igor Cima; Nadia Corazza; Bernhard Dick; Andrea Fuhrer; Simon Herren; Sabine Jakob; Erick Ayuni; Christoph Mueller; Thomas Brunner
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

5.  Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Authors:  Amy K Wesa; Maja Mandic; Jennifer L Taylor; Stergios Moschos; John M Kirkwood; William W Kwok; James Harold Finke; Walter J Storkus
Journal:  Front Oncol       Date:  2014-09-29       Impact factor: 6.244

6.  Liver receptor homolog-1 (NR5a2) regulates CD95/Fas ligand transcription and associated T-cell effector functions.

Authors:  Juliane Schwaderer; Ann-Kathrin Gaiser; Truong San Phan; M Eugenia Delgado; Thomas Brunner
Journal:  Cell Death Dis       Date:  2017-04-13       Impact factor: 8.469

7.  The orphan nuclear receptor LRH-1/NR5a2 critically regulates T cell functions.

Authors:  Carina Seitz; Juan Huang; Anna-Lena Geiselhöringer; Pamela Galbani-Bianchi; Svenja Michalek; Truong San Phan; Cindy Reinhold; Lea Dietrich; Christian Schmidt; Nadia Corazza; Eugenia Delgado; Theresa Schnalzger; Kristina Schoonjans; Thomas Brunner
Journal:  Sci Adv       Date:  2019-07-17       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.